Infectious disease market size to grow by USD 104.81 billion between 2022 and 2027; Growth driven by the increasing prevalence of infectious diseases - Technavio

Rhea-AI Summary

The infectious disease market is projected to grow by USD 104.81 billion from 2022 to 2027, at a CAGR of 12.49%, driven by the rising prevalence of infectious diseases and a robust drug pipeline. North America is expected to account for 42% of this growth, bolstered by significant investments and a favorable reimbursement scenario. Key segments include drugs and vaccines, with drugs anticipated to see substantial growth due to new antifungal treatments in development. Challenges such as anti-microbial resistance and adverse drug effects may impede progress. Overall, strategic alliances and R&D advancements will shape the competitive landscape.

Positive

• Projected market growth of USD 104.81 billion from 2022 to 2027.
• CAGR of 12.49% during the forecast period.
• North America expected to contribute 42% of market growth due to strong pharmaceutical presence.

Negative

• Challenges include adverse effects of anti-infective drugs and anti-microbial resistance.

NEW YORK, April 3, 2023 /PRNewswire/ -- The infectious disease market size is forecasted to increase by USD 104.81 billion from 2022 to 2027, at a CAGR of 12.49%, according to the recent market study by Technavio. The growth of the market will be driven by the increasing prevalence of infectious diseases, the growing awareness of infectious diseases, and the strong drug pipeline. Charts & data tables about market and segment sizes for a historic period (2017-2021) and forecast period (2023-2027) have been covered in this report. Download the Sample Report

Vendor Analysis

The global infectious disease market has a presence of numerous regional and international vendors that compete on price points and product quality. Considering the cost-intensive nature of vaccine manufacturing and the expertise of these players in the market, Technavio expects the competitive landscape to remain the same during the forecast period. The market has many companies, and strategic alliances of new entrants with existing companies are expected to lead to vendor dilution to some extent during the forecast period. Some of the key vendors covered in the report include:

• Bio Rad Laboratories Inc.: The company offers solutions for infectious diseases, which enable earlier diagnosis, appropriate therapy selection, personalized care, and infectious disease monitoring.
• Danaher Corp.: The company offers solutions for infectious diseases, which help in preventing disease transmission by diagnosing infection, monitoring treatment, and providing essential educational training for healthcare workers.
• F. Hoffmann La Roche Ltd.: The company offers solutions for infectious diseases using testing systems, reagents, and quality controls to optimize testing workflows and provide quality results.
• Genetic Signatures Ltd.: The company offers solutions for infectious diseases by providing tests for the early detection of infectious diseases in the fields of antimicrobial resistance and healthcare-associated infections.
• Grifols SA
• Hologic Inc.
• Meridian Bioscience Inc.
• Meril Life Sciences Pvt. Ltd.
• OraSure Technologies Inc.
• PerkinElmer Inc.
• QIAGEN NV
• Siemens AG
• Sysmex Corp.
• Trinity Biotech Plc
• Abbott Laboratories

Why Buy?

• Add credibility to strategy
• Analyzes competitor's offerings
• Get a holistic view of the market

Grow your profit margin with Technavio - Buy the Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Get a holistic overview of the endoscopic closure devices market by industry experts to
evaluate and develop growth strategies. Download the Sample

Market Segmentation:

The market is segmented by product (drugs and vaccines), end-user (hospital, multispecialty clinic, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).

By product, the market growth will be significant in the drug segment during the forecast period. The increase in the incidence of fungal infections can be attributed to the rise in chronic diseases such as cancer. Moreover, the R&D of safer antifungals with improved spectra is underway. Currently, there are promising molecules in the pipeline for antifungal treatment, including PC945 by Pulmocide, F901318 by F2G, isavuconazole by Astellas Pharma, and caspofungin acetate by Merck. These molecules are expected to change market dynamics when they are launched during the forecast period.

By end-user, the market will witness increased demand for hospitals during the forecast period. Factors such as the increasing number of patients with infectious diseases have led to the high demand for infectious disease diagnosis. Certain developed countries, such as the US, have a positive reimbursement scenario, which contributes to the increasing adoption of infectious disease diagnosis. Such factors will increase segment growth during the forecast period.

North America will account for 42% of the market growth during the forecast period. The regional market is led by the US because of the presence of top players such as Gilead, Johnson and Johnson, Pfizer, and AbbVie, which generate high revenue from their leading drugs. In addition, these vendors invest in marketing and patient awareness initiatives. Factors such as the development and launch of drugs for the treatment of infectious diseases, and proper treatment of the patient population will drive the market growth in this region during the forecast period.

Market Dynamics:

Key Drivers:

• Increasing prevalence of infectious diseases
• Growing awareness of infectious diseases
• Strong drug pipeline

The increasing prevalence of infectious diseases is the key factor driving the market growth. These Infectious diseases are caused by organisms such as bacteria, viruses, fungi, and parasites. The pattern of infectious disease incidence has also been changing, with the evolution of drug-resistant pathogens. HIV/AIDS is a leading cause of death in many countries. Moreover, globally, the incidence and prevalence of infectious diseases have increased due to climate change and its consequences. This is expected to be a major driver for market growth during the forecast period.

Major Trends:

• Development of novel drugs
• Increasing mergers and acquisition
• Emergence of new patterns of infectious diseases

The development of novel drugs will fuel market growth. There has been an increase in the R&D of novel drugs for the treatment of infectious diseases. According to researchers, a new drug called pranlukast can kill the tuberculosis bacterium as well as weaken its survival strategies within cells. This discovery will provide an opportunity to use this novel drug combination in tuberculosis therapeutics. Such developments are expected to have a positive impact on the growth of the market during the forecast period.

Key Challenges:

• Adverse effects of anti-infective drugs
• Slowdown in the manufacturing industry
• Anti-microbial resistance (AMR)

The adverse effects of anti-infective drugs are a major challenge to market growth. Multiple drugs are being approved by the US FDA and are being indicated for the treatment of different infectious diseases. However, these drugs are associated with adverse effects. For instance, Saquinavir is an antiviral medicine that prevents the human immunodeficiency virus (HIV) from multiplying in the patient's body. The drug has some life-threatening side effects if it is taken along with cholesterol medication (such as Mevacor, Altoprev, and Advicor) and heart rhythm medications (including amiodarone, disopyramide, and dofetilide). The adverse effects of anti-infective drugs can reduce patient compliance, thereby leading to a decline in the growth of the market.

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

What are the key data covered in this Infectious Disease Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the infectious disease market between 2023 and 2027
• Precise estimation of the infectious disease market size and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the infectious disease market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of infectious disease market vendors

Related Reports: 

• The infectious disease diagnostics market size is estimated to grow at a CAGR of 6.7% between 2021 and 2026. The addiction therapeutics market size is forecast to increase by USD 13.94 billion. The market is segmented by end-user (hospitals and labs) and geography (North America, Europe, Asia, and Rest of World (ROW)). 
• The infectious enteritis treatment market is expected to develop at the market's growth momentum (CAGR) of 5.09% between 2021 and 2026 and the market size is expected to increase by USD 403.92 million. The market is segmented by route of administration (oral and injectables) and geography (North America, Europe, Asia, and Rest of World (ROW))

Infectious Disease Market Scope
Report Coverage	Details
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 12.49%
Market growth 2023-2027	USD 104.81 billion
Market structure	Fragmented
YoY growth 2022-2023 (%)	11.16
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 42%
Key countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Bio Rad Laboratories Inc., Danaher Corp., F. Hoffmann La Roche Ltd., Genetic Signatures Ltd., Grifols SA, Hologic Inc., Meridian Bioscience Inc., Meril Life Sciences Pvt. Ltd., OraSure Technologies Inc., PerkinElmer Inc., QIAGEN NV, Siemens AG, Sysmex Corp., Trinity Biotech Plc, Abbott Laboratories, Becton Dickinson and Co., bioMerieux SA, DiaSorin SpA, Quidel Corp., and Thermo Fisher Scientific Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse through Technavio's Health Care Market Reports

Table of contents:

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022 

• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global infectious disease market 2017 - 2021
• Exhibit 18: Historic Market Size – Data Table on Global infectious disease market 2017 - 2021 ($ billion)

• 4.2 Product Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ billion)

• 4.3 End-user Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size – End-user Segment 2017 - 2021 ($ billion)

• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)

• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

• 6.1 Market segments 
• Exhibit 30: Chart on Product - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Product - Market share 2022-2027 (%)

• 6.2 Comparison by Product 
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product

• 6.3 Drugs - Market size and forecast 2022-2027
• Exhibit 34: Chart on Drugs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 35: Data Table on Drugs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 36: Chart on Drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Drugs - Year-over-year growth 2022-2027 (%)

• 6.4 Vaccines - Market size and forecast 2022-2027
• Exhibit 38: Chart on Vaccines - Market size and forecast 2022-2027 ($ billion)
• Exhibit 39: Data Table on Vaccines - Market size and forecast 2022-2027 ($ billion)
• Exhibit 40: Chart on Vaccines - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Vaccines - Year-over-year growth 2022-2027 (%)

• 6.5 Market opportunity by Product 
• Exhibit 42: Market opportunity by Product ($ billion)

7 Market Segmentation by End-user

• 7.1 Market segments 
• Exhibit 43: Chart on End-user - Market share 2022-2027 (%)
• Exhibit 44: Data Table on End-user - Market share 2022-2027 (%)

• 7.2 Comparison by End-user 
• Exhibit 45: Chart on Comparison by End-user
• Exhibit 46: Data Table on Comparison by End-user

• 7.3 Hospital - Market size and forecast 2022-2027
• Exhibit 47: Chart on Hospital - Market size and forecast 2022-2027 ($ billion)
• Exhibit 48: Data Table on Hospital - Market size and forecast 2022-2027 ($ billion)
• Exhibit 49: Chart on Hospital - Year-over-year growth 2022-2027 (%)
• Exhibit 50: Data Table on Hospital - Year-over-year growth 2022-2027 (%)

• 7.4 Multispecialty clinic - Market size and forecast 2022-2027 
• Exhibit 51: Chart on Multispecialty clinic - Market size and forecast 2022-2027 ($ billion)
• Exhibit 52: Data Table on Multispecialty clinic - Market size and forecast 2022-2027 ($ billion)
• Exhibit 53: Chart on Multispecialty clinic - Year-over-year growth 2022-2027 (%)
• Exhibit 54: Data Table on Multispecialty clinic - Year-over-year growth 2022-2027 (%)

• 7.5 Others - Market size and forecast 2022-2027
• Exhibit 55: Chart on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibit 56: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibit 57: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on Others - Year-over-year growth 2022-2027 (%)

• 7.6 Market opportunity by End-user 
• Exhibit 59: Market opportunity by End-user ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 61: Chart on Market share by geography 2022-2027 (%)
• Exhibit 62: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 63: Chart on Geographic comparison
• Exhibit 64: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Germany - Market size and forecast 2022-2027
• Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.9 China - Market size and forecast 2022-2027
• Exhibit 89: Chart on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 90: Data Table on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 91: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.10 UK - Market size and forecast 2022-2027
• Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.11 Japan - Market size and forecast 2022-2027
• Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ billion)
• Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ billion)
• Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 101: Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers 

• 10.2 Market challenges 

• 10.3 Impact of drivers and challenges 
• Exhibit 102: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends 

11 Vendor Landscape

• 11.1 Overview 

• 11.2 Vendor landscape 
• Exhibit 103: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 104: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 105: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 106: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 107: Matrix on vendor position and classification

• 12.3 Abbott Laboratories 
• Exhibit 108: Abbott Laboratories - Overview
• Exhibit 109: Abbott Laboratories - Business segments
• Exhibit 110: Abbott Laboratories - Key news
• Exhibit 111: Abbott Laboratories - Key offerings
• Exhibit 112: Abbott Laboratories - Segment focus

• 12.4 Becton Dickinson and Co. 
• Exhibit 113: Becton Dickinson and Co. - Overview
• Exhibit 114: Becton Dickinson and Co. - Business segments
• Exhibit 115: Becton Dickinson and Co. - Key news
• Exhibit 116: Becton Dickinson and Co. - Key offerings
• Exhibit 117: Becton Dickinson and Co. - Segment focus

• 12.5 Bio Rad Laboratories Inc. 
• Exhibit 118: Bio Rad Laboratories Inc. - Overview
• Exhibit 119: Bio Rad Laboratories Inc. - Business segments
• Exhibit 120: Bio Rad Laboratories Inc. - Key news
• Exhibit 121: Bio Rad Laboratories Inc. - Key offerings
• Exhibit 122: Bio Rad Laboratories Inc. - Segment focus

• 12.6 bioMerieux SA 
• Exhibit 123: bioMerieux SA - Overview
• Exhibit 124: bioMerieux SA - Product / Service
• Exhibit 125: bioMerieux SA - Key offerings

• 12.7 Danaher Corp. 
• Exhibit 126: Danaher Corp. - Overview
• Exhibit 127: Danaher Corp. - Business segments
• Exhibit 128: Danaher Corp. - Key news
• Exhibit 129: Danaher Corp. - Key offerings
• Exhibit 130: Danaher Corp. - Segment focus

• 12.8 DiaSorin SpA 
• Exhibit 131: DiaSorin SpA - Overview
• Exhibit 132: DiaSorin SpA - Business segments
• Exhibit 133: DiaSorin SpA - Key news
• Exhibit 134: DiaSorin SpA - Key offerings
• Exhibit 135: DiaSorin SpA - Segment focus

• 12.9 F. Hoffmann La Roche Ltd. 
• Exhibit 136: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 137: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 138: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 139: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 140: F. Hoffmann La Roche Ltd. - Segment focus

• 12.10 Meridian Bioscience Inc. 
• Exhibit 141: Meridian Bioscience Inc. - Overview
• Exhibit 142: Meridian Bioscience Inc. - Business segments
• Exhibit 143: Meridian Bioscience Inc. - Key offerings
• Exhibit 144: Meridian Bioscience Inc. - Segment focus

• 12.11 OraSure Technologies Inc. 
• Exhibit 145: OraSure Technologies Inc. - Overview
• Exhibit 146: OraSure Technologies Inc. - Business segments
• Exhibit 147: OraSure Technologies Inc. - Key offerings
• Exhibit 148: OraSure Technologies Inc. - Segment focus

• 12.12 PerkinElmer Inc. 
• Exhibit 149: PerkinElmer Inc. - Overview
• Exhibit 150: PerkinElmer Inc. - Business segments
• Exhibit 151: PerkinElmer Inc. - Key news
• Exhibit 152: PerkinElmer Inc. - Key offerings
• Exhibit 153: PerkinElmer Inc. - Segment focus

• 12.13 QIAGEN NV 
• Exhibit 154: QIAGEN NV - Overview
• Exhibit 155: QIAGEN NV - Product / Service
• Exhibit 156: QIAGEN NV - Key news
• Exhibit 157: QIAGEN NV - Key offerings

• 12.14 Quidel Corp. 
• Exhibit 158: Quidel Corp. - Overview
• Exhibit 159: Quidel Corp. - Product / Service
• Exhibit 160: Quidel Corp. - Key offerings

• 12.15 Siemens AG 
• Exhibit 161: Siemens AG - Overview
• Exhibit 162: Siemens AG - Business segments
• Exhibit 163: Siemens AG - Key news
• Exhibit 164: Siemens AG - Key offerings
• Exhibit 165: Siemens AG - Segment focus

• 12.16 Thermo Fisher Scientific Inc. 
• Exhibit 166: Thermo Fisher Scientific Inc. - Overview
• Exhibit 167: Thermo Fisher Scientific Inc. - Business segments
• Exhibit 168: Thermo Fisher Scientific Inc. - Key news
• Exhibit 169: Thermo Fisher Scientific Inc. - Key offerings
• Exhibit 170: Thermo Fisher Scientific Inc. - Segment focus

• 12.17 Trinity Biotech Plc 
• Exhibit 171: Trinity Biotech Plc - Overview
• Exhibit 172: Trinity Biotech Plc - Product / Service
• Exhibit 173: Trinity Biotech Plc - Key offerings

13 Appendix

• 13.1 Scope of the report 

• 13.2 Inclusions and exclusions checklist
• Exhibit 174: Inclusions checklist
• Exhibit 175: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 176: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 177: Research methodology
• Exhibit 178: Validation techniques employed for market sizing
• Exhibit 179: Information sources

• 13.5 List of abbreviations 
• Exhibit 180: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/infectious-disease-market-size-to-grow-by-usd-104-81-billion-between-2022-and-2027-growth-driven-by-the-increasing-prevalence-of-infectious-diseases---technavio-301786009.html

SOURCE Technavio

FAQ

What is the forecasted growth of the infectious disease market from 2022 to 2027?

The infectious disease market is projected to grow by USD 104.81 billion from 2022 to 2027.

What is the CAGR of the infectious disease market?

The CAGR of the infectious disease market is forecasted to be 12.49%.

How much of the market growth will North America account for?

North America is expected to account for 42% of the market growth during the forecast period.

What challenges does the infectious disease market face?

Key challenges include adverse effects of anti-infective drugs and anti-microbial resistance.

What segments are driving growth in the infectious disease market?

Growth is primarily driven by the drug segment, specifically through the development of new antifungal treatments.